BioSpace News Archive

IMV Inc. today announced the finalization of the basket clinical study evaluating maveropepimut-S.

Precision Molecular, Inc. today announced it has executed a licensing agreement with Johns Hopkins University for exclusive rights to an astatine-211-labeled inhibitor of prostate-specific membrane antigen (PSMA) which is typically elevated in prostate cancer cells.

Precision BioSciences, Inc. today announced that it has entered into an agreement with a syndicate of investors led by ACCELR8 to separate its wholly owned Elo Life Systems subsidiary and create an independent food and agriculture business.

XOMA Corporation announced its Chief Executive Officer, Jim Neal, will present at the following upcoming investor conferences:

Cybin Inc. is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will participate in two upcoming virtual investor conferences.

Heat Biologics, Inc. today announced it has executed a definitive merger agreement to acquire Elusys Therapeutics, a commercial-stage biodefense company and the manufacturer of ANTHIM® (obiltoxaximab) Injection, pursuant to which Elusys will merge into a wholly owned subsidiary of Heat.

Volta Medical, a pioneering health tech company developing artificial intelligence (AI)-based software solutions to treat cardiac arrythmias, today announced the introduction of its leading-edge product, VX1, at three leading U.S. hospitals.

TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced the full readout of safety and pharmacokinetic (PK) data from its Phase 1b study (NCT #04576325) of Inhaled Voriconazole Powder (TFF VORI) in asthma patients.

Biomea Fusion, Inc. announced that it will present at the upcoming virtual 40th Annual J.P. Morgan Healthcare Conference.

Hoth Therapeutics, Inc. announced it submitted an Orphan Drug Designation Request to the US Food and Drug Administration (FDA) for HT-KIT for the treatment of mastocytosis.